14 February 2016

Virotec teams up with TerraPlus

Aim-listed green technology firm Virotec has signed an important Memorandum of Understanding with Iberian-based engineering consultant TerraPlus, writes James Crux.

Formerly listed as a mining venture Down Under, Virotec (VTI) has worldwide marketing and distribution rights to Bauxsol, a 'green' technology that neutralises acid and removes heavy metals from environmentally contaminated water.

Recent estimates suggest that the market for the technology could be worth 100 billion. In today's announcement, the Virotec board said that engineering consultant TerraPlus had 'already identified potential opportunities in the Portuguese and Spanish mining industries' to use Virotec's Bauxsol technology. TerraPlus full name TerraPlus Engenharia Do Ambiente E Fiscalizacao LDA has a strong presence in the civil engineering, mineral extraction, water management and sanitation services fields. Under the terms of the MOU, TerraPlus will be Virotec's exclusive licensed agent in Portugal and a non-exclusive licensed agent in Spain, with Virotec supplying the actual Bauxsol technology as well as technical support, on a project-by-project basis.

Today's news appears to be a significant strategic development for the company. At a recent meeting with journalists, executive chairman Brian Sheeran said that 'our aim is not only to protect the environment, but to do it in an economically appealing way that will save mining companies money. We came to Aim to internationalise the technology and be first to market'. In line with this strategy, Virotec recently opened up an Italian subsidiary, Virotec Italia, operating from Rome. The Italian office is working to secure permits and licences for the transportation and application of its Bauxsol technology across the European Union, while other offices will be opened across Europe.

The chemicals-listed company floated on Aim in July following a placing of 27.5 million new shares at 14p, which raised 3.36 million net. The shares were unchanged at 15.75p on today's news, valuing the business at 21.65 million.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gresham brings private equity expertise to small listed stocks

There are many smaller company funds out there; but the new management of Gresham House Strategic (AIM: GHS) is trying to stand out from the crowd by bringing a ‘private equity’ approach to the public market arena. For investors who supplement their own ‘DIY’ stock picking with selected funds, GHS could be an interesting option.

Diurnal to profit from orphan drugs

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

More News